Fusion Pharmaceuticals Stock Annual Yield
Fusion Pharmaceuticals fundamentals help investors to digest information that contributes to Fusion Pharmaceuticals' financial success or failures. It also enables traders to predict the movement of Fusion Stock. The fundamental analysis module provides a way to measure Fusion Pharmaceuticals' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Fusion Pharmaceuticals stock.
Fusion |
Fusion Pharmaceuticals Company Annual Yield Analysis
Fusion Pharmaceuticals' Yield generally refers to the amount of cash that is paid back to the owner of a security over a specific time (usually one year). It is expressed as a percentage of current market price, and usually amounts to all the interests and/or dividends paid over a given period. A higher yield allows the shareholders to generate returns on their investments sooner. However, investors should also be aware that a high yield may be a result of market turmoil or increased price volatility.
Small firms, start-ups, or companies with high growth potential typically do not pay out dividends or distribute a lot of their profits. These companies will have small yield. Alternatively, more established companies, ETFs, and funds that invest in bonds will have higher yields.
CompetitionIn accordance with the recently published financial statements, Fusion Pharmaceuticals has an Annual Yield of 0.0%. This indicator is about the same for the Biotechnology average (which is currently at 0.0) sector and about the same as Health Care (which currently averages 0.0) industry. This indicator is about the same for all United States stocks average (which is currently at 0.0).
Did you try this?
Run Headlines Timeline Now
Headlines TimelineStay connected to all market stories and filter out noise. Drill down to analyze hype elasticity |
All Next | Launch Module |
Fusion Fundamentals
Return On Equity | -0.47 | |||
Return On Asset | -0.23 | |||
Operating Margin | (54.04) % | |||
Current Valuation | 1.69 B | |||
Shares Outstanding | 85.06 M | |||
Shares Owned By Insiders | 0.46 % | |||
Shares Owned By Institutions | 86.80 % | |||
Number Of Shares Shorted | 3.06 M | |||
Price To Book | 8.13 X | |||
Price To Sales | 874.50 X | |||
Revenue | 2.07 M | |||
Gross Profit | (57.43 M) | |||
EBITDA | (97.89 M) | |||
Net Income | (94.9 M) | |||
Cash And Equivalents | 198.42 M | |||
Cash Per Share | 4.57 X | |||
Total Debt | 50.33 M | |||
Debt To Equity | 0.08 % | |||
Current Ratio | 17.89 X | |||
Book Value Per Share | 2.85 X | |||
Cash Flow From Operations | (81.8 M) | |||
Short Ratio | 6.22 X | |||
Earnings Per Share | (1.40) X | |||
Target Price | 21.14 | |||
Number Of Employees | 101 | |||
Beta | -0.69 | |||
Market Capitalization | 1.83 B | |||
Total Asset | 285.84 M | |||
Retained Earnings | (376.76 M) | |||
Working Capital | 227.18 M | |||
Net Asset | 285.84 M |
Pair Trading with Fusion Pharmaceuticals
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Fusion Pharmaceuticals position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Fusion Pharmaceuticals will appreciate offsetting losses from the drop in the long position's value.The ability to find closely correlated positions to Verizon Communications could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Verizon Communications when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Verizon Communications - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Verizon Communications to buy it.
The correlation of Verizon Communications is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Verizon Communications moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Verizon Communications moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Verizon Communications can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Investing Opportunities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in state. You can also try the Portfolio Manager module to state of the art Portfolio Manager to monitor and improve performance of your invested capital.
Other Consideration for investing in Fusion Stock
If you are still planning to invest in Fusion Pharmaceuticals check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Fusion Pharmaceuticals' history and understand the potential risks before investing.
Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
Top Crypto Exchanges Search and analyze digital assets across top global cryptocurrency exchanges | |
Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
Bonds Directory Find actively traded corporate debentures issued by US companies | |
Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity | |
Global Markets Map Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes | |
FinTech Suite Use AI to screen and filter profitable investment opportunities | |
Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets |